Patients with PD who experience these complications often receive other anti-PD drugs in combination with levodopa, including dopamine agonists (DAs), monoamine oxidase type B inhibitors (MAOBIs), catechol-O-methyl transferase inhibitors (COMTIs), and adenosine A2A receptor antagonist (A2ARA)2,3. The gene discussed is ADORA2A; the disease is Parkinson disease.